ARCHIVES

Lasofoxifene Reduced Breast Cancer Risk In Postmenopausal Osteoporotic Women

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

DeVita: “The War On Cancer Is Dead”

June 11, 2010

FDA Advisors Give Dox-SL Conditional Approval; Ok Zoladex

February 24, 1995

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

June 28, 2013

FDA Accepts Advisory Committee’s Recommendations On NDA, Labeling

October 26, 1979

Also in this 8-page issue: Dana-Farber opens center for advanced cancer science.

April 23, 2004

Science Fellowships Available; Grants For Former Soviet Scientists

August 16, 1996